This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
World Health Organization. The Importance of Pharmacovigilance: safety monitoring of medicinal products (2002). http://apps.who.int/medicinedocs/en/d/Js4893e/. Assessed 19 Dec 2017.
Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36:75–81.
van Grootheest K, de Graaf L, de Jong-van den Berg LTW. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf. 2003;26:211–7.
Banovac M, Candore G, Slattery J, Houÿez F, Haerry D, Genov G, et al. Patient reporting in the EU: analysis of eudravigilance data. Drug Saf. 2017;40:629–45.
Borg J-J, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? Drug Saf. 2011;34:187–97.
Matos C, Härmark L, van Hunsel F. Patient reporting of adverse drug reactions: an international survey of national competent authorities’ views and needs. Drug Saf. 2016;39:1105–16.
Arlett PR, Kurz X. New approaches to strengthen pharmacovigilance. Drug Discov Today Technol. 2011;8:e15–9.
Inácio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83:227–46.
van Hunsel F, de Waal S, Härmark L. The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015. Pharmacoepidemiol Drug Saf. 2017;26:977–83.
Watson S, Chandler RE, Taavola H, Härmark L, Grundmark B, Zekarias A, et al. Safety concerns reported by patients identified in a collaborative signal detection workshop using vigibase: results and reflections from lareb and uppsala monitoring centre. Drug Saf. 2018;41:203–12.
Inch J, Watson MC, Anakwe-Umeh S. Patient versus healthcare professional spontaneous adverse drug reaction reporting. Drug Saf. 2012;35:807–18.
Rolfes L, van Hunsel F, Taxis K, van Puijenbroek E. the impact of experiencing adverse drug reactions on the patient’s quality of life: a retrospective cross-sectional study in the Netherlands. Drug Saf. 2016;39:769–76.
Rolfes L, van Hunsel F, van der Linden L, Taxis K, van Puijenbroek E. The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis. Drug Saf. 2017;40:607–14.
Al Dweik R, Stacey D, Kohen D, Yaya S. Factors affecting patient reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol. 2017;83:875–83.
Jadeja M, Inglefield P. An evaluation of the EU wide social media campaign to raise awareness of national spontaneous ADR reporting systems (2017). http://www.scopejointaction.eu/_assets/files/2017-01-17-SCOPE-ADR-social-media-campaign-evaluation-FINAL-Mitul-Jadeja.pdf. Assessed 14 Dec 2017.
Kaeding M, Schmälter J, Klika C. Pharmacovigilance in the European Union. Wiesbaden: Springer Fachmedien Wiesbaden; 2017.
van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K. Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf. 2012;35:45–60.
Durrieu G, Jacquot J, Mège M, Bondon-Guitton E, Rousseau V, Montastruc F, et al. Completeness of spontaneous adverse drug reaction reports sent by general practitioners to a regional pharmacovigilance centre: a descriptive study. Drug Saf. 2016;39:1189–95.
Kheloufi F, Default A, Rouby F, Laugier-Castellan D, Boyer M, Rodrigues B, et al. Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre? Eur J Clin Pharmacol. 2017;73:1009–18.
Inácio P, Cavaco A, Allan E, Airaksinen M. Key pharmacovigilance stakeholders’ experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union. Public Health. 2018;155:119–28.
Martins SF, van Mil JWF, da Costa FA. The organizational framework of community pharmacies in Europe. Int J Clin Pharm. 2015;37:896–905.
Leone R, Moretti U, D’Incau P, Conforti A, Magro L, Lora R, et al. effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study. Drug Saf. 2013;36:267–76.
Parretta E, Rafaniello C, Magro L, Coggiola Pittoni A, Sportiello L, Ferrajolo C, et al. Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy. Expert Opin Drug Saf. 2014;13:21–9.
Bigi C, Bocci G. The key role of clinical and community health nurses in pharmacovigilance. Eur J Clin Pharmacol. 2017;73:1379–87.
Härmark L, van Grootheest K. Web-based intensive monitoring: from passive to active drug surveillance. Expert Opin Drug Saf. 2012;11:45–51.
Bhattacharya M, Snyder S, Malin M, Truffa MM, Marinic S, Engelmann R, et al. Using social media data in routine pharmacovigilance: a pilot study to identify safety signals and patient perspectives. Pharm Med. 2017;31:167–74.
Defer G, Le Caignec F, Fedrizzi S, Montastruc F, Chevanne D, Parienti J-J, et al. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial. Trials BioMed Cent. 2018;19:174.
No funding was provided for the completion of this commentary.
Conflicts of interest
Authors have completed the conflict of interest disclosure form and declare no financial relationships with any organizations that might have an interest in the submitted work. There are no other relationships or activities that could appear to have influenced the submitted work. Authors have no support from any organization for the submitted work.
About this article
Cite this article
Inácio, P., Cavaco, A. & Airaksinen, M. Current trends in pharmacovigilance: value and gaps of patient reporting. Int J Clin Pharm 40, 754–757 (2018). https://doi.org/10.1007/s11096-018-0689-6